Critical Contrast: Imprivata (IMPR) vs. Its Rivals
Imprivata (NYSE: IMPR) is one of 97 publicly-traded companies in the “Enterprise Software” industry, but how does it contrast to its rivals? We will compare Imprivata to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.
This is a breakdown of recent ratings and price targets for Imprivata and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Enterprise Software” companies have a potential upside of 3.20%. Given Imprivata’s rivals higher probable upside, analysts clearly believe Imprivata has less favorable growth aspects than its rivals.
Institutional and Insider Ownership
59.3% of Imprivata shares are held by institutional investors. Comparatively, 59.4% of shares of all “Enterprise Software” companies are held by institutional investors. 40.2% of Imprivata shares are held by company insiders. Comparatively, 23.4% of shares of all “Enterprise Software” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Imprivata and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Imprivata and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Imprivata Competitors||$1.27 billion||$348.14 million||36.48|
Imprivata’s rivals have higher revenue and earnings than Imprivata. Imprivata is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Imprivata has a beta of -1.21, suggesting that its stock price is 221% less volatile than the S&P 500. Comparatively, Imprivata’s rivals have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.
Imprivata rivals beat Imprivata on 5 of the 8 factors compared.
Imprivata, Inc. (Imprivata) is a United States-based healthcare information technology security company. The Company enables healthcare organizations to access, communicate and transact patient information securely. The Company offers Imprivata OneSign, Imprivata Cortext, Imprivata Confirm ID and Imprivata PatientSecure. Imprivata OneSign provides single sign-on, authentication management and virtual desktop roaming, enabling No Click Access to clinical applications and patient information, anytime, anywhere and from any device. Imprivata Cortext enables clinicians to collaborate across care teams and organizations. Imprivata Confirm ID is an identity and two-factor authentication platform for remote access, electronic prescriptions for controlled substances (EPCS), medical device access and other clinical authentication workflows. Imprivata PatientSecure is a patient identification solution that uses palm vein recognition biometrics to identify patients at any point of entry to care.
Receive News & Stock Ratings for Imprivata Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprivata Inc and related stocks with our FREE daily email newsletter.